SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis

Cancer Letters

Volumn 278, Issue 1, 2009, Pages 41-48

  Felix, Roberta S ^a   Colleoni, Gisele W B ^a   Caballero, Otavia L ^b   Yamamoto, Mihoko ^a   Almeida, Manuella S S ^a   Andrade, Valéria C C ^a   Chauffaille, Maria de Lourdes L F ^a   Silva Jr , Wilson A da ^c   Begnami, Maria Dirlei ^d   Soares, Fernando Augusto ^d   Simpson, Andrew J ^b   Zago, Marco Antonio ^c   Vettore, André L ^e  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d A C CAMARGO CANCER CENTER   (Brazil)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

Author keywords

Gene expression profiling; Meta analysis; Multiple myeloma; SAGE

Indexed keywords

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DDX5 GENE; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; MALE; MAPKAPK2 GENE; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; P53CSV GENE; PALATINE TONSIL; PLASMA CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANBP2 GENE; REAL TIME POLYMERASE CHAIN REACTION; SERIAL ANALYSIS OF GENE EXPRESSION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; DEAD-BOX RNA HELICASES; DNA PRIMERS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; MOLECULAR CHAPERONES; MULTIPLE MYELOMA; NEOPLASM STAGING; NUCLEAR PORE COMPLEX PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES; SYNDECAN-1; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 63649122933     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.12.022     Document Type: Article

References (24)

1. Kyle R.A., and Rajkumar S.V. Multiple myeloma. New Engl. J. Med. 351 (2004) 1860-1873
2. Barlogie B. High-dose therapy and innovative approaches to pretreatment of multiple myeloma. Semin. Hematol. 38 (2001) 1-7
3. Harousseau J.L., Shaughnessy Jr. J., and Richardson P. Multiple myeloma. Am. Soc. Hematol. Educ. Program. (2004) 237-256
4. Orlowski R.Z. Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation. Am. Soc. Hematol. Educ. Program. (2006) 338-347
5. Zhan F., Hardin J., Kordsmeier B., Bumm K., Zheng M., Tian E., Sanderson R., Yang Y., Wilson C., Zangari M., Anaissie E., Morris C., et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99 (2002) 1745-1757
6. Magrangeas F., Nasser V., Avet-Loiseau H., Loriod B., Decaux O., Granjeaud S., Bertucci F., Birnbaum D., Nguyen C., Harousseau J.L., Bataille R., Houlgatte R., et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 101 (2003) 4998-5006
7. Velculescu V.E., Zhang L., Vogelstein B., and Kinzler K.W. Serial analysis of gene expression. Science 270 (1995) 484-487
8. International Myeloma Working Group, Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, Br. J. Haematol. 121 (2003) 749-757.
9. Greipp P.R., San Miguel J., Durie B.G., Crowley J.J., Barlogie B., Bladé J., Boccadoro M., Child J.A., Avet-Loiseau H., Kyle R.A., Lahuerta J.J., Ludwig H., et al. International staging system for multiple myeloma. J. Clin. Oncol. 23 (2005) 3412-3420
10. Kumar S., Witzig T.E., Timm M., Haug J., Wellik L., Kimlinger T.K., Greipp P.R., and Rajkumar S.V. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 104 (2004) 1159-1165
11. Condomines M., Hose D., Raynaud P., Hundemer M., De Vos J., Baudard M., Moehler T., Pantesco V., Moos M., Schved J.F., Rossi J.F., Rème T., et al. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J. Immunol. 178 (2007) 3307-3315
12. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
13. Zhan F., Barlogie B., Arzoumanian V., Huang Y., Williams D.R., Hollmig K., Pineda-Roman M., Tricot G., van Rhee F., Zangari M., Dhodapkar M., and Shaughnessy Jr. J.D. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109 (2007) 1692-1700
14. Mattioli M., Agnelli L., Fabris S., Baldini L., Morabito F., Bicciato S., Verdelli D., Intini D., Nobili L., Cro L., Pruneri G., Callea V., et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 24 (2005) 2461-2473
15. Agnelli L., Fabris S., Bicciato S., Basso D., Baldini L., Morabito F., Verdelli D., Todoerti K., Lambertenghi-Deliliers G., Lombardi L., and Neri A. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br. J. Haematol. 136 (2007) 565-573
16. Carrasco D.R., Tonon G., Huang Y., Zhang Y., Sinha R., Feng B., Stewart J.P., Zhan F., Khatry D., Protopopova M., Protopopov A., Sukhdeo K., et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9 (2006) 313-325
17. Zhan F., Hardin J., Kordsmeier B., Bumm K., Zheng M., Tian E., Sanderson R., Yang Y., Wilson C., Zangari M., Anaissie E., Morris C., et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99 (2002) 1745-1757
18. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., and Chinnaiyan A.M. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc. Natl. Acad. Sci. USA 101 (2004) 9309-9314
19. Lal A., Lash A.E., Altschul S.F., et al. A public database for gene expression in human cancers. Cancer Res. 59 (1999) 5403-5407
20. Zhan F., Barlogie B., and Shaughnessy J. Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling. Semin. Hematol. 40 4 (2003) 308-320
21. Park W.R., and Nakamura Y. p53CSV, a novel p53-inducible gene involved in the p53-dependent cell-survival pathway. Cancer Res. 65 (2005) 1197-1206
22. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Kung A.L., Davies F.E., Morgan G., Akiyama M., Shringarpure R., Munshi N.C., Richardson P.G., Hideshima T., et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 107 (2006) 1092-1100
23. Fuller-Pace F.V., Jacobs A.M., and Nicol S.M. Modulation of transcriptional activity of the DEAD-box family of RNA helicases, p68 (Ddx5) and DP103 (Ddx20), by SUMO modification. Biochem. Soc. Trans. 35 (2007) 1427-1429
24. Hideshima T., Podar K., Chauhan D., Ishitsuka K., Mitsiades C., Tai Y.T., Hamasaki M., Raje N., Hideshima H., Schreiner G., Nguyen A.N., Navas T., et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23 (2004) 8766-8776